A study to evaluate the safety, tolerance and changes in blood levels of an anti-toxin drug (FBT-002) in healthy male and female subjects

2023-505745-16-00 Human pharmacology (Phase I) - First administration to humans Ended

Start 5 Jan 2024 · End 30 Sep 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 24
Countries 1
Sites 1

Antidote

Key facts

Sponsor
Eurofins Optimed, Fabentech
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
5 Jan 2024 → 30 Sep 2024
Decision date (initial)
2023-12-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Antidote

VersionLevelCodeTermSystem organ class
20.0 LLT 10015711 Exposure to poisonous plant 10022117

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Eurofins Optimed

Sponsor organisation
Eurofins Optimed
Address
1 Rue Des Essarts
City
Gieres
Postcode
38610
Country
France

Scientific contact point

Organisation
Eurofins Optimed
Contact name
Félix COLLET

Public contact point

Organisation
Eurofins Optimed
Contact name
Félix COLLET

Fabentech

Sponsor organisation
Fabentech
Address
Building Tony Garnier, 24 Rue Jean Baldassini 24 Rue Jean Baldassini
City
Lyon
Postcode
69007
Country
France

Scientific contact point

Organisation
Fabentech
Contact name
Romane ARLAUD

Public contact point

Organisation
Fabentech
Contact name
Romane ARLAUD

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 24 1
Rest of world 0

Investigational sites

France

1 site · Ended
Eurofins Optimed
Clinical pharmacology unit, 1 Rue Des Essarts, 38610, Gieres

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-01-05 2024-09-30 2024-01-05 2024-08-01

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-20 France Acceptable with conditions
2023-12-19
2023-12-20
2 SUBSTANTIAL MODIFICATION SM-1 2023-12-21 France Acceptable
2023-12-22
2023-12-22
3 SUBSTANTIAL MODIFICATION SM-2 2024-01-16 France 2024-03-04
4 SUBSTANTIAL MODIFICATION SM-3 2024-03-05 France Acceptable
2024-04-22
2024-04-22
5 NON SUBSTANTIAL MODIFICATION NSM-2 2024-04-24 France Acceptable
2024-04-22
2024-04-24
6 SUBSTANTIAL MODIFICATION SM-4 2024-07-04 France Acceptable
2024-08-02
2024-08-02
7 SUBSTANTIAL MODIFICATION SM-5 2024-08-09 France Acceptable
2024-08-29
2024-08-30